InMode
INMD Small CapHealthcare · Medical Devices
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
InMode en bref
InMode (INMD) is currently trading at 13,13 € with a market capitalization of 755 M €. The trailing P/E ratio stands at 11.21x, with a forward P/E of 10.46x. The 52-week range spans from 11,03 € to 14,51 €; the current price is 9.6% below the yearly high. Year-over-year revenue growth stands at +5.3%. The net profit margin stands at 23.27%.
💰 Dividende
InMode currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
3 analystes évaluent InMode (INMD) au consensus : None. L'objectif de cours moyen est de 13,29 €, soit un potentiel de +1.28% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 12,14 € à 14,74 €.
InMode : la thèse d'investissement en détail
InMode (INMD) operates in the Healthcare — specifically Medical Devices — and is headquartered in Israel. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 77.84%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 23.27%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.
Le scénario baissier
With a beta near 1.91, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.
Valorisation en contexte
With a PEG ratio of 0.83, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 5.31x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
Thèse d'investissement : forces et faiblesses
- Rentable avec une marge nette de 23.27%
- Marge brute élevée de 77.84% — signe d'un pouvoir de fixation des prix
- Actuellement jugée sous-évaluée
- Bilan solide avec faible endettement (D/E 0.73)
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to above-average price swings, elevated short interest (5.9%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy InMode?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news